Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson/’s disease.<br>Rasagiline inhibits rat brain MAO type B and type A with IC50 of 4.43 nM and 412 nM, respectively. Rasagiline is three to 15 times more potent than selegiline for inhibition of MAO-B in rat brain and liver in vivo on acute and chronic administration, but has similar potency in vitro.<br>Rasagiline ex vivo inhibits MAO in the brain and liver with ED50 of 4.43 nM and 412 nM, respectively.
| Catalog Number | A001151 |
| CAS Number | 161735-79-1 |
| Synonyms | TVP-1012 |
| Molecular Formula | C₁₂H₁₃N ∙ CH₃SO₃H |
| Purity | ≥95% |
| Target | MAO |
| Solubility | Soluble in DMSO > 10 mM |
| Storage | 3 years -20C powder |
| InChI | InChI=1S/C12H13N.CH4O3S/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12;1-5(2,3)4/h1,3-6,12-13H,7-9H2;1H3,(H,2,3,4)/t12-;/m1./s1 |
| InChIKey | JDBJJCWRXSVHOQ-UTONKHPSSA-N |
| SMILES | CS(=O)(=O)O.C#CCNC1CCC2=CC=CC=C12 |
